9,739 reports of this reaction
9.9% of all VENETOCLAX reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for VENETOCLAX, manufactured by AbbVie Inc.. There are 9,739 FDA adverse event reports linking VENETOCLAX to DEATH. This represents approximately 9.9% of all 98,823 adverse event reports for this drug.
VENETOCLAX has an overall safety score of 88 out of 100. Patients taking VENETOCLAX who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among VENETOCLAX users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for VENETOCLAX:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 9,739 FDA reports for VENETOCLAX. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 9.9% of all adverse event reports for VENETOCLAX, making it one of the most commonly reported side effect.
If you experience death while taking VENETOCLAX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.